Research Site

Bridgeton, Missouri 63044

5 studies enrolling now · 19 studies all time

What they study most

Acute Ischaemic Stroke, Asthma, COPD, Carcinoma, Non-Small Cell Lung, Cardiovascular Disease, Chronic Obstructive Pulmonary Disease, Cost Sharing, Acute Coronary Syndrome, Diabetes Mellitus, Type 2, Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD), Hairy Cell Leukemia, Healthy, Moderate to Very Severe COPD

Studies at this site

• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer — Recruiting now
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) — Recruiting now
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC — Recruiting now
• A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event — Recruiting now
• Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations — Recruiting now
• Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer — Recruiting now
• US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI) — Stopped early
• Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma — Completed
• Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia — Completed
• A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis — Completed
• A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes — Completed
• Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study — Completed
• Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients. — Completed
• Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus — Completed
• [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] — Completed
• A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents — Completed
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children — Completed
• A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants — Completed
• An Observational Study to Assess Respiratory Syncytial Virus (RSV) Respiratory Events Among Premature Infants — Completed